POMT2-related limb-girdle muscular dystrophy R14

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:206559OMIM:613158G71.0
Who is this for?
Show terms as
2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

POMT2-related limb-girdle muscular dystrophy R14 (LGMDR14), formerly known as LGMD2N, is a rare autosomal recessive muscular dystrophy caused by biallelic pathogenic variants in the POMT2 gene. POMT2 encodes protein O-mannosyltransferase 2, an enzyme essential for the proper glycosylation of alpha-dystroglycan, a key protein that links the muscle cell cytoskeleton to the extracellular matrix. Defective glycosylation of alpha-dystroglycan leads to a group of conditions collectively known as dystroglycanopathies. LGMDR14 represents the milder end of the POMT2-related disease spectrum, with the more severe end including Walker-Warburg syndrome and muscle-eye-brain disease. Patients with LGMDR14 typically present in childhood or adolescence with progressive proximal muscle weakness predominantly affecting the limb-girdle muscles — the muscles around the hips and shoulders. This leads to difficulty climbing stairs, rising from the floor, running, and lifting the arms overhead. Elevated serum creatine kinase (CK) levels are a hallmark laboratory finding. Cognitive impairment of variable severity, including intellectual disability, may be present in some patients, reflecting the role of alpha-dystroglycan in brain development. Muscle biopsy typically shows dystrophic changes with reduced immunostaining for glycosylated alpha-dystroglycan. There is currently no cure or disease-specific treatment for LGMDR14. Management is supportive and multidisciplinary, including physical therapy to maintain mobility and prevent contractures, orthopedic interventions as needed, respiratory monitoring, cardiac surveillance, and neurodevelopmental support when cognitive involvement is present. Genetic counseling is recommended for affected families. Research into therapies targeting the dystroglycanopathy pathway, including gene therapy and pharmacological approaches to enhance glycosylation, is ongoing but remains in early stages.

Also known as:

Clinical phenotype terms— hover any for plain English:

Limb-girdle muscular dystrophyHP:0006785Reduced muscle fiber alpha dystroglycanHP:0030099Proximal amyotrophyHP:0007126Fatigable weakness of skeletal musclesHP:0030197Scapuloperoneal amyotrophyHP:0003697Frontal cortical atrophyHP:0006913Complete right bundle branch blockHP:0011712Left ventricular systolic dysfunctionHP:0025169
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for POMT2-related limb-girdle muscular dystrophy R14.

View clinical trials →

No actively recruiting trials found for POMT2-related limb-girdle muscular dystrophy R14 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the POMT2-related limb-girdle muscular dystrophy R14 community →

Specialists

2 foundView all specialists →
SB
Sofie T. Østergaard, Bsc.
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to POMT2-related limb-girdle muscular dystrophy R14.

Search all travel grants →NORD Financial Assistance ↗

Community

Open POMT2-related limb-girdle muscular dystrophy R14Forum →

No community posts yet. Be the first to share your experience with POMT2-related limb-girdle muscular dystrophy R14.

Start the conversation →

Latest news about POMT2-related limb-girdle muscular dystrophy R14

No recent news articles for POMT2-related limb-girdle muscular dystrophy R14.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about POMT2-related limb-girdle muscular dystrophy R14

What is POMT2-related limb-girdle muscular dystrophy R14?

POMT2-related limb-girdle muscular dystrophy R14 (LGMDR14), formerly known as LGMD2N, is a rare autosomal recessive muscular dystrophy caused by biallelic pathogenic variants in the POMT2 gene. POMT2 encodes protein O-mannosyltransferase 2, an enzyme essential for the proper glycosylation of alpha-dystroglycan, a key protein that links the muscle cell cytoskeleton to the extracellular matrix. Defective glycosylation of alpha-dystroglycan leads to a group of conditions collectively known as dystroglycanopathies. LGMDR14 represents the milder end of the POMT2-related disease spectrum, with the m

How is POMT2-related limb-girdle muscular dystrophy R14 inherited?

POMT2-related limb-girdle muscular dystrophy R14 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat POMT2-related limb-girdle muscular dystrophy R14?

2 specialists and care centers treating POMT2-related limb-girdle muscular dystrophy R14 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.